local_hospital

Medical Center Mentalcare Ltd.

Address
lock Available on a paid plan

Behavioral Disciplines and Activities

Medical Center Mentalcare Ltd. conducts research aimed at improving the treatment of anxiety and depressive disorders. Trials explore new adjunctive therapies and novel drug candidates for Generalized Anxiety Disorder and Major Depressive Disorder, seeking better symptom control and relapse prevention.

  • Adjunctive therapy for treatment‑resistant depression
  • Monotherapy approaches for generalized anxiety
  • Evaluation of relapse‑prevention strategies
  • Safety and tolerability assessments of new psychiatric agents

The site’s ongoing work aims to expand therapeutic options for patients with mood and anxiety disorders, with the hope of enhancing quality of life.

Mental Disorders

In the field of mental disorders, the center focuses on schizophrenia and severe mood conditions. Studies assess the impact of innovative adjunctive medications and target symptom reduction in Schizophrenia and complex depressive presentations.

  • Adjunctive treatment for inadequately controlled schizophrenia
  • Assessment of novel antipsychotic agents
  • Long‑term safety monitoring of psychiatric drugs
  • Combination strategies for severe depressive symptoms

Through these investigations, Medical Center Mentalcare Ltd. contributes to advancing care for individuals living with serious mental illnesses.

Site Overview

assignment
15
connected trials
corporate_fare
7
sponsors
science
9
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
15
Total trials linked
Highly Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
8
Sponsors (total)
7
Active sponsors
4

Sponsor Network

Top 4 by active trials.

lock +3 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +4 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 476 other sites in Bulgaria

description
Trial volume
15
Outperforms 81% of sites
public
Therapeutic diversity
2areas
Outperforms 47% of sites
groups
Sponsor diversity
7sponsors
Outperforms 72% of sites

Therapeutic Area Benchmark — Bulgaria

Select a therapeutic area to compare against other sites in Bulgaria.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Bulgaria

Market Share

Country: Bulgaria

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Medical Center Mentalcare Ltd.

lock Showing 1 of 15 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety DisorderOtsuka Pharmaceutical Development & Commercialization Inc.Phase IVNot RecruitingSep 2023Sep 2025

IMP list

lock Showing 1 of 9 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Aticaprant3Unknown2023-06-122024-12-04

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.